funding to be sourced from partnership deals that will deliver much in the way of capital resources, but will sacrifice percent ownership in the resulting mergers that Cyrus will negotiate to fruition, but because Leronlimab is so versatile and flexible, Cyrus will capitalize on this attribute of Leronlimab and garner greater and increased upfront capital from the partnering companies in exchange for greater and increased percentages for them and less for CytoDyn for the sale of Leronlimab.